The FDA expanded the label for Rhythm Pharmaceuticals’ Imcivree to include adults and children aged 4 and up with acquired hypothalamic obesity, making it the first approved therapy for that condition. Clinical data showed Imcivree delivered meaningful weight loss versus placebo; Rhythm expects the decision to expand its addressable patient base and bolster revenue growth for a company that has posted consecutive losses. Separately, Johnson & Johnson and partner Protagonist secured FDA approval for Icotyde (icotrokinra), an oral IL‑23 receptor antagonist for moderate‑to‑severe plaque psoriasis. The approval gives the firms an oral alternative to injectable IL‑23 biologics and could drive switch dynamics in dermatology prescribing.